Literature DB >> 32656709

Effects of thiamine and fenofibrate on high glucose and hypoxia-induced damage in cell models of the inner blood-retinal barrier.

Aurora Mazzeo1, Chiara Gai1, Marina Trento1, Massimo Porta1, Elena Beltramo2.   

Abstract

AIMS: Although diabetic retinopathy has long been considered a microvascular complication, retinal neurodegeneration and inflammation may precede its clinical manifestations. Despite all research efforts, the primary treatment options remain laser photocoagulation and anti-vascular endothelial growth factor (VEGF) intravitreal injections, both aggressive and targeting the late stages of the disease. Medical treatments addressing the early phases of diabetic retinopathy are therefore needed. We aimed at verifying if thiamine and fenofibrate protect the cells of the inner blood-retinal barrier from the metabolic stress induced by diabetic-like conditions.
METHODS: Human microvascular endothelial cells (HMECs), retinal pericytes (HRPs) and Müller cells (MIO-M1) were cultured in intermittent high glucose (intHG) and/or hypoxia, with addition of fenofibrate or thiamine. Modulation of adhesion molecules and angiogenic factors was addressed.
RESULTS: Integrins β1/αVβ3 and ICAM1 were upregulated in HMECs/HRPs cultured in diabetic-like conditions, as well as metalloproteases MMP2/9 in HRP, with a reduction in their inhibitor TIMP1; MMP2 increased also in HMEC, and TIMP1 decreased in MIO-M1. VEGF and HIF-1α were strongly increased in HMEC in intHG + hypoxia, and VEGF also in HRP. Ang-1/2 augmented in HMEC/MIO-M1, and MCP-1 in HRP/MIO-M1 in intHG + hypoxia. Thiamine was able to normalize all such abnormal modulations, while fenofibrate had effects in few cases only.
CONCLUSIONS: We suggest that endothelial cells and pericytes are more affected than Müller cells by diabetic-like conditions. Fenofibrate shows a controversial behavior, potentially positive on Müller cells and pericytes, but possibly detrimental to endothelium, while thiamine confirms once more to be an effective agent in reducing diabetes-induced retinal damage.

Entities:  

Keywords:  Diabetic retinopathy; Fenofibrate; Hyperglycemia; Hypoxia; Inner blood-retinal barrier; Thiamine

Mesh:

Substances:

Year:  2020        PMID: 32656709     DOI: 10.1007/s00592-020-01565-x

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  41 in total

1.  Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy.

Authors:  Sumon Roy; Dongjoon Kim; Cristina Hernández; Rafael Simó; Sayon Roy
Journal:  Exp Eye Res       Date:  2015-08-18       Impact factor: 3.467

Review 2.  Endothelial/pericyte interactions.

Authors:  Annika Armulik; Alexandra Abramsson; Christer Betsholtz
Journal:  Circ Res       Date:  2005-09-16       Impact factor: 17.367

Review 3.  Modulation of microglia in the retina: new insights into diabetic retinopathy.

Authors:  Ana I Arroba; Ángela M Valverde
Journal:  Acta Diabetol       Date:  2017-03-27       Impact factor: 4.280

4.  Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.

Authors:  Hans-Peter Hammes; Xueliang Du; Diane Edelstein; Tetsuya Taguchi; Takeshi Matsumura; Qida Ju; Jihong Lin; Angelika Bierhaus; Peter Nawroth; Dieter Hannak; Michael Neumaier; Regine Bergfeld; Ida Giardino; Michael Brownlee
Journal:  Nat Med       Date:  2003-02-18       Impact factor: 53.440

Review 5.  Müller cells and diabetic retinopathy.

Authors:  Brandon A Coughlin; Derrick J Feenstra; Susanne Mohr
Journal:  Vision Res       Date:  2017-09-05       Impact factor: 1.886

6.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Authors:  A C Keech; P Mitchell; P A Summanen; J O'Day; T M E Davis; M S Moffitt; M-R Taskinen; R J Simes; D Tse; E Williamson; A Merrifield; L T Laatikainen; M C d'Emden; D C Crimet; R L O'Connell; P G Colman
Journal:  Lancet       Date:  2007-11-07       Impact factor: 79.321

7.  Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine.

Authors:  Roya Babaei-Jadidi; Nikolaos Karachalias; Naila Ahmed; Sinan Battah; Paul J Thornalley
Journal:  Diabetes       Date:  2003-08       Impact factor: 9.461

8.  High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease.

Authors:  P J Thornalley; R Babaei-Jadidi; H Al Ali; N Rabbani; A Antonysunil; J Larkin; A Ahmed; G Rayman; C W Bodmer
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

9.  Thiamine transporter 2 is involved in high glucose-induced damage and altered thiamine availability in cell models of diabetic retinopathy.

Authors:  Elena Beltramo; Aurora Mazzeo; Tatiana Lopatina; Marina Trento; Massimo Porta
Journal:  Diab Vasc Dis Res       Date:  2019-11-14       Impact factor: 3.291

10.  Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models.

Authors:  Ying Chen; Yang Hu; Mingkai Lin; Alicia J Jenkins; Anthony C Keech; Robert Mott; Timothy J Lyons; Jian-xing Ma
Journal:  Diabetes       Date:  2012-10-05       Impact factor: 9.461

View more
  1 in total

Review 1.  Regulations of Retinal Inflammation: Focusing on Müller Glia.

Authors:  Yingying Chen; Qinghong Xia; Yue Zeng; Yun Zhang; Meixia Zhang
Journal:  Front Cell Dev Biol       Date:  2022-04-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.